Physician profile

Warren Conway

Family Medicine · San Angelo, TX

NPI 1245290717

$12,333.62

in general payments reported to CMS, 2019-2025

44 companies · $838 in 2025

The $838 reported for 2025 was more than what 83% of Family Medicine providers received nationally (typical 2025 total: $153).

Payments by year

General payments by program year, as reported to CMS.

What the payments were for

Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.

View as a table
Payment typeAmount (2023-2025)
Food and Beverage$3,630.60
Travel and Lodging$3,152.61

Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.

Who reported paying

General payments only, as reported to CMS. Product names cover 2023-2025.

CompanyGeneral paymentsYearsTop products
Modernatx, INC. $3,829.62 2023
Novo Nordisk INC $2,008.34 2019-2025 Rybelsus, Ozempic, Wegovy
Abbvie INC. $1,288.61 2020-2025 Vraylar, Ubrelvy, Qulipta
Astrazeneca Pharmaceuticals Lp $828.28 2019-2025 Breztri, Farxiga, Airsupra
Lilly USA, LLC $446.78 2019-2025 Mounjaro, Zepbound
Boehringer Ingelheim Pharmaceuticals, INC. $399.44 2019-2025 Jardiance
Takeda Pharmaceuticals U.S.A., INC. $372.87 2019-2022
Allergan, INC. $332.54 2019-2020
Pfizer INC. $316.15 2019-2025
Amgen INC. $302.35 2019-2024 Evenity, Prolia
Exact Sciences Corporation $256.80 2023-2025 Cologuard Collection Kit
Merck Sharp & Dohme LLC $229.44 2019-2022
Sanofi-Aventis U.S. LLC $186.07 2019-2023
Glaxosmithkline, LLC. $185.48 2019-2024 Arexvy, Trelegy Ellipta, Shingrix
Amarin Pharma, INC. $153.16 2019-2022
Show all 41 companies
CompanyGeneral paymentsYearsTop products
Otsuka America Pharmaceutical, INC. $151.03 2021-2025 Rexulti
Janssen Pharmaceuticals, INC $125.52 2019-2021
Lundbeck LLC $108.91 2024-2025 Rexulti, Vyepti
Biohaven Pharmaceuticals, INC. $96.07 2021
Salix Pharmaceuticals, A Division of Bausch Health US, LLC $79.99 2021-2025 Xifaxan
Biohaven Pharmaceutical Holding Company Ltd. $57.15 2022
Supernus Pharmaceuticals, INC. $55.80 2021-2022
Arbor Pharmaceuticals, INC. $52.79 2019-2021
Dexcom, INC. $52.25 2020-2025 Dexcom G6 Transmitter
Abbott Laboratories $44.60 2022-2025 Octrode
Mylan Specialty L.P. $34.81 2024 Yupelri
Dynavax Technologies Corporation $33.94 2021-2022
Kowa Pharmaceuticals America, INC. $32.18 2019-2021
Ironshore Pharmaceuticals INC. $31.72 2019
Phathom Pharmaceuticals, INC. $28.99 2025 Voquezna
Novartis Pharmaceuticals Corporation $28.59 2021
Corium, LLC $24.55 2022
Eisai INC. $23.96 2020
Zyla Life Sciences, INC. $21.59 2020
Iti, INC. (D/B/A Intra-Cellular Therapies, INC.) $20.83 2022
Sanofi Pasteur INC. $20.07 2021
Collegium Pharmaceutical, INC. $15.69 2025 Jornay Pm
Tris Pharma INC $15.46 2024 Dyanavel Xr
Axsome Therapeutics, INC. $14.87 2025 Auvelity
E.R. Squibb & Sons, L.L.C. $14.60 2025 Eliquis
Redhill Biopharma INC. $11.73 2020

3 companies reported research payments only; those appear in the research section below.

Drugs and devices associated with these payments

CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.

If you want to bring it up

Most clinicians are glad to talk about this. A respectful way in:

These are normal questions. A good clinician will welcome them.

Share this page

Payment summary

Warren Conway

$12,333.62

in general payments reported 2019-2025

Years
2019-2025
Top company
Modernatx, INC.
Context
The $838 reported for 2025 was more than what 83% of Family Medicine providers received nationally (typical 2025 total: $153).

https://glasscript.com/doctor/55844/warren-conway

Source: CMS Open Payments, program years 2019-2025. Payments are legal and often routine.

Keep an eye on this page

Get an email when the next June refresh changes this page. No account needed.

Watch this doctor

Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.